Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.015 EUR
279.84 K EUR
0.00 EUR
15.24 M
About HERANTIS PHARMA OYJ
Sector
CEO
Antti Vuolanto
Headquarters
Espoo
Website
Founded
2008
ISIN
FI4000087861
FIGI
BBG006GWBH62
Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. It offers medicinal products such as Cis-UCA eye drops for dry eye, CDNF for Parkinson's disease, Lymfactin for secondary lymphedema, Cis-UCA emulsion cream for atopic dermatitis, and CDNF for amyotrophic lateral sclerosis (ALS). The company was founded by Eero Hemminki Castren, Henri Juhani Huttunen, Heikki Rauvala, and Mart Saarma in 2008 and is headquartered in Espoo, Finland.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of HRTIS is 1.555 EUR — it has decreased by −5.76% in the past 24 hours. Watch HERANTIS PHARMA OYJ stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXHEX exchange HERANTIS PHARMA OYJ stocks are traded under the ticker HRTIS.
HRTIS stock has fallen by −5.47% compared to the previous week, the month change is a 17.80% rise, over the last year HERANTIS PHARMA OYJ has showed a −0.32% decrease.
We've gathered analysts' opinions on HERANTIS PHARMA OYJ future price: according to them, HRTIS price has a max estimate of 2.20 EUR and a min estimate of 2.20 EUR. Watch HRTIS chart and read a more detailed HERANTIS PHARMA OYJ stock forecast: see what analysts think of HERANTIS PHARMA OYJ and suggest that you do with its stocks.
HRTIS reached its all-time high on Jun 11, 2014 with the price of 10.460 EUR, and its all-time low was 0.730 EUR and was reached on Jul 18, 2016. View more price dynamics on HRTIS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
HRTIS stock is 6.45% volatile and has beta coefficient of −0.13. Track HERANTIS PHARMA OYJ stock price on the chart and check out the list of the most volatile stocks — is HERANTIS PHARMA OYJ there?
Today HERANTIS PHARMA OYJ has the market capitalization of 31.35 M, it has decreased by −0.60% over the last week.
Yes, you can track HERANTIS PHARMA OYJ financials in yearly and quarterly reports right on TradingView.
HERANTIS PHARMA OYJ is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
HRTIS earnings for the last half-year are −0.14 EUR per share, whereas the estimation was −0.12 EUR, resulting in a −13.92% surprise. The estimated earnings for the next half-year are −0.12 EUR per share. See more details about HERANTIS PHARMA OYJ earnings.
HERANTIS PHARMA OYJ revenue for the last half-year amounts to 5.00 K EUR, despite the estimated figure of 0.00 EUR. In the next half-year revenue is expected to reach 5.00 K EUR.
HRTIS net income for the last half-year is −2.69 M EUR, while the previous report showed 2.08 M EUR of net income which accounts for −229.49% change. Track more HERANTIS PHARMA OYJ financial stats to get the full picture.
No, HRTIS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 27, 2024, the company has 10.00 employees. See our rating of the largest employees — is HERANTIS PHARMA OYJ on this list?
Like other stocks, HRTIS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HERANTIS PHARMA OYJ stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HERANTIS PHARMA OYJ technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HERANTIS PHARMA OYJ stock shows the neutral signal. See more of HERANTIS PHARMA OYJ technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.